Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries
Objective The emergence of resistance-associated substitutions (RASs) poses a significant challenge to the effective treatment of hepatitis C virus (HCV) infection using direct-acting antivirals. This study’s objective was to observe the prevalence of HCV genotypes and RAS within the Former Soviet U...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | BMJ Open Gastroenterology |
| Online Access: | https://bmjopengastro.bmj.com/content/12/1/e001657.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823858049824063488 |
|---|---|
| author | Sten H Vermund Salima Davlidova Syed Hani Abidi Syed Ali Robert Heimer Aidana Mustafa Dinara Begimbetova |
| author_facet | Sten H Vermund Salima Davlidova Syed Hani Abidi Syed Ali Robert Heimer Aidana Mustafa Dinara Begimbetova |
| author_sort | Sten H Vermund |
| collection | DOAJ |
| description | Objective The emergence of resistance-associated substitutions (RASs) poses a significant challenge to the effective treatment of hepatitis C virus (HCV) infection using direct-acting antivirals. This study’s objective was to observe the prevalence of HCV genotypes and RAS within the Former Soviet Union (FSU) countries.Methods We analysed 60 NS3, 313 NS5A and 1119 NS5B sequences of HCV deposited in open-access databases from 11 FSU countries for the prevalence of genotypes and the presence of RAS using the Geno2Pheno software.Results The following NS3 RASs were revealed through our analyses: 156P/S/T, 168del, 80K, 55A and 174S. The most prevalent NS5A RAS was 30K (12.69%) in genotype 3a, associated with resistance to daclatasvir, elbasvir and ledipasvir, followed by 62S (8.96% in genotype 3a), linked with resistance to daclatasvir, and 93H (3.95% and 6.72% in genotypes 1b and 3a, respectively), conferring resistance to daclatasvir, ombitasvir, elbasvir, ledipasvir and velpatasvir. The NS5B RASs found in this study were 451S and 556G, associated with resistance to dasabuvir.Conclusion The high prevalence of HCV genotypes 1b and 3a in the FSU region and the presence of specific RASs should be considered when determining the most effective treatment regimen for HCV-infected individuals in the FSU countries. |
| format | Article |
| id | doaj-art-6ccdc305209a445ea979e9f018798ba2 |
| institution | Kabale University |
| issn | 2054-4774 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Gastroenterology |
| spelling | doaj-art-6ccdc305209a445ea979e9f018798ba22025-02-11T16:05:09ZengBMJ Publishing GroupBMJ Open Gastroenterology2054-47742025-01-0112110.1136/bmjgast-2024-001657Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countriesSten H Vermund0Salima Davlidova1Syed Hani Abidi2Syed Ali3Robert Heimer4Aidana Mustafa5Dinara Begimbetova6Yale University, New Haven, Connecticut, USANazarbayev University, Astana, KazakhstanDepartment of Biomedical Sciences, Nazarbayev University School of Medicine, Astana, KazakhstanDepartment of Biomedical Sciences, Nazarbayev University School of Medicine, Astana, KazakhstanYale University, New Haven, Connecticut, USADepartment of Biomedical Sciences, Nazarbayev University School of Medicine, Astana, KazakhstanNational Laboratory Astana, Nazarbayev University, Astana, KazakhstanObjective The emergence of resistance-associated substitutions (RASs) poses a significant challenge to the effective treatment of hepatitis C virus (HCV) infection using direct-acting antivirals. This study’s objective was to observe the prevalence of HCV genotypes and RAS within the Former Soviet Union (FSU) countries.Methods We analysed 60 NS3, 313 NS5A and 1119 NS5B sequences of HCV deposited in open-access databases from 11 FSU countries for the prevalence of genotypes and the presence of RAS using the Geno2Pheno software.Results The following NS3 RASs were revealed through our analyses: 156P/S/T, 168del, 80K, 55A and 174S. The most prevalent NS5A RAS was 30K (12.69%) in genotype 3a, associated with resistance to daclatasvir, elbasvir and ledipasvir, followed by 62S (8.96% in genotype 3a), linked with resistance to daclatasvir, and 93H (3.95% and 6.72% in genotypes 1b and 3a, respectively), conferring resistance to daclatasvir, ombitasvir, elbasvir, ledipasvir and velpatasvir. The NS5B RASs found in this study were 451S and 556G, associated with resistance to dasabuvir.Conclusion The high prevalence of HCV genotypes 1b and 3a in the FSU region and the presence of specific RASs should be considered when determining the most effective treatment regimen for HCV-infected individuals in the FSU countries.https://bmjopengastro.bmj.com/content/12/1/e001657.full |
| spellingShingle | Sten H Vermund Salima Davlidova Syed Hani Abidi Syed Ali Robert Heimer Aidana Mustafa Dinara Begimbetova Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries BMJ Open Gastroenterology |
| title | Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries |
| title_full | Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries |
| title_fullStr | Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries |
| title_full_unstemmed | Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries |
| title_short | Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries |
| title_sort | prevalence of resistance associated substitutions ras in hepatitis c virus in the former soviet union countries |
| url | https://bmjopengastro.bmj.com/content/12/1/e001657.full |
| work_keys_str_mv | AT stenhvermund prevalenceofresistanceassociatedsubstitutionsrasinhepatitiscvirusintheformersovietunioncountries AT salimadavlidova prevalenceofresistanceassociatedsubstitutionsrasinhepatitiscvirusintheformersovietunioncountries AT syedhaniabidi prevalenceofresistanceassociatedsubstitutionsrasinhepatitiscvirusintheformersovietunioncountries AT syedali prevalenceofresistanceassociatedsubstitutionsrasinhepatitiscvirusintheformersovietunioncountries AT robertheimer prevalenceofresistanceassociatedsubstitutionsrasinhepatitiscvirusintheformersovietunioncountries AT aidanamustafa prevalenceofresistanceassociatedsubstitutionsrasinhepatitiscvirusintheformersovietunioncountries AT dinarabegimbetova prevalenceofresistanceassociatedsubstitutionsrasinhepatitiscvirusintheformersovietunioncountries |